Thomas Jay Simon
Physician at Ivymont Rd, Rosemont, PA
License number
Colorado 24780
Issued Date
Jul 8, 1982
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
1114 Ivymont Rd, Rosemont, PA 19010
Professional information
Dr. Thomas J Simon, Bryn Mawr PA - MD (Doctor of Medicine)
Specialties:
Gastroenterology
Address:
1114 Ivymont Rd, Bryn Mawr 19010
(610) 527-1827 (Phone)
(610) 527-1827 (Phone)
Certifications:
Gastroenterology, 1985, Internal Medicine, 1982
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of California At San Diego
University of California At San Diego
Combination Therapy For Treating Cyclooxygenase-2 Mediated Diseases Or Conditions In Patients At Risk Of Thrombotic Cardiovascular Events
US Patent:
2008009, Apr 24, 2008
Filed:
Aug 19, 2005
Appl. No.:
11/660195
Inventors:
Thomas Simon - Bryn Mawr PA, US
Alise Reicin - Englewood NJ, US
Richard Hunt - Ontario, CA
Alise Reicin - Englewood NJ, US
Richard Hunt - Ontario, CA
International Classification:
A61K 31/4439, A61K 31/365, A61K 31/444, A61P 19/00, A61P 9/00
US Classification:
514334000, 514338000, 514473000
Abstract:
The invention encompasses a pharmaceutical composition comprising a therapeutically effective amount of a cyclooxygenase-2 selective inhibitor selected from rofecoxib and etoricoxib or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a proton pump inhibitor selected from the group consisting of: omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole, or a pharmaceutically acceptable salt of any of the aforementioned, in combination with a pharmaceutically acceptable carrier. The invention also encompasses a method for treating a cyclooxygenase-2 mediated disease or condition in a human patient at risk of a thrombotic cardiovascular event, wherein the patient is on aspirin therapy to reduce the risk of the thrombotic cardiovascular event, comprising administering to the patient this pharmaceutical composition.
Combination Therapy For Treating Cyclooxygenase-2 Mediated Diseases In Patients At Risk Of Thrombotic Cardiovascular Events
US Patent:
2005021, Sep 29, 2005
Filed:
May 9, 2003
Appl. No.:
10/513085
Inventors:
Richard Hunt - Burlington, CA
Thomas Simon - Bryn Mawr PA, US
Thomas Simon - Bryn Mawr PA, US
International Classification:
A61K031/415
US Classification:
514406000
Abstract:
The present invention encompasses a method for treating a chronic cyclooxygenase-2 mediated disease or condition and reducing the risk of a thrombotic cardiovascular event in a human patient in need of such treatment and at risk of a thrombotic cardiovascular event comprising orally concomitantly or sequentially administering to said patient a cyclooxygenase-2 selective inhibitor in an amount effective to treat the cyclooxygenase-2 mediated disease or condition and nitric oxide releasing aspirin in an amount effective to reduce the risk of the thrombotic cardiovascular event while maintaining a high level of upper gastrointestinal safety and tolerability. The invention also encompasses a method for treating a chronic cyclooxygenase-2 mediated disease or condition and reducing the risk of a thrombotic cardiovascular event in a human patient in need of such treatment and at risk of a thrombotic cardiovascular event comprising orally concomitantly or sequentially administering to said patient a nitric oxide releasing-cyclooxygenase-2 selective inhibitor in an amount effective to treat the cyclooxygenase-2 mediated disease or condition and aspirin in an amount effective to reduce the risk of the thrombotic cardiovascular event while maintaining a high level of upper gastrointestinal safety and tolerability. Pharmaceutical compositions are also encompassed.